4887

SAWAI GROUP HOLDINGS Co., Ltd.

サワイグループホールディングス株式会社
Pharmaceutical
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.
← Companies
Price
¥1,749
Market Cap
¥201.9B
Ent. Value
¥254.5B
Net Debt
−¥52.6B
Shares Out.
115.5M
P / E
18.1×
EV / EBIT
62.8×
P / Book
—
P / NCAV
10.07×
Div. Yield
6.00%
Financials
Metric FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥189.0B ¥176.9B ¥200.3B ¥193.8B
Cost of Sales ¥132.7B ¥122.5B ¥137.7B ¥127.2B
Gross Profit ¥56.4B ¥54.3B ¥62.6B ¥66.7B
SG&A ¥23.5B ¥23.2B ¥30.2B ¥46.7B
Operating Income ¥4.0B ¥18.6B ¥17.0B ¥-35.9B
Non-Operating Income ¥151M ¥201M ¥213M ¥145M
Non-Operating Expenses ¥1.0B ¥558M ¥407M ¥471M
Pre-tax Income ¥3.2B ¥18.3B ¥16.8B ¥-36.2B
Net Income (owners) ¥12.0B ¥13.7B ¥12.7B ¥-28.3B
Minority Interest — ¥-4.5B ¥169M ¥-13.7B
Comprehensive Income ¥407M ¥13.3B ¥18.2B ¥-35.0B
EBITDA ¥19.3B ¥36.7B ¥34.7B ¥-18.8B
EPS ¥96.54 ¥312.67 ¥289.25 ¥-645.53
Shares Outstanding 115.5M 43.8M 43.8M 43.8M
Shares Issued (total) 131.5M 43.8M 43.8M 43.8M
Treasury Shares 16.0M 0.0M 0.0M 0.0M